Algert Global LLC Buys New Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Algert Global LLC bought a new stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) in the 2nd quarter, Holdings Channel.com reports. The firm bought 14,808 shares of the company’s stock, valued at approximately $35,000.

Several other large investors have also bought and sold shares of ALLO. Lynx1 Capital Management LP acquired a new position in shares of Allogene Therapeutics in the 2nd quarter valued at $5,192,000. Price T Rowe Associates Inc. MD boosted its position in shares of Allogene Therapeutics by 76.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock valued at $18,675,000 after purchasing an additional 1,806,147 shares during the period. Renaissance Technologies LLC boosted its position in shares of Allogene Therapeutics by 340.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company’s stock valued at $4,073,000 after purchasing an additional 1,351,055 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Allogene Therapeutics by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock valued at $5,944,000 after purchasing an additional 507,021 shares during the period. Finally, TD Asset Management Inc boosted its position in shares of Allogene Therapeutics by 82.7% in the 2nd quarter. TD Asset Management Inc now owns 799,340 shares of the company’s stock valued at $1,862,000 after purchasing an additional 361,904 shares during the period. Institutional investors own 83.63% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on ALLO. Canaccord Genuity Group decreased their price target on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a research note on Thursday, August 15th. Citigroup increased their price objective on Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Oppenheimer assumed coverage on Allogene Therapeutics in a research note on Thursday, August 8th. They issued an “outperform” rating and a $11.00 price objective for the company. Finally, Truist Financial reissued a “buy” rating and issued a $14.00 price objective (down from $17.00) on shares of Allogene Therapeutics in a research note on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.96.

Allogene Therapeutics Stock Up 1.1 %

Shares of NASDAQ:ALLO opened at $2.65 on Friday. Allogene Therapeutics, Inc. has a 12 month low of $2.01 and a 12 month high of $5.78. The company’s 50-day moving average price is $2.62 and its two-hundred day moving average price is $2.82. The firm has a market cap of $554.14 million, a P/E ratio of -1.65 and a beta of 0.83.

Allogene Therapeutics (NASDAQ:ALLO) last issued its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative return on equity of 50.24%. As a group, equities analysts predict that Allogene Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).